Mangoceuticals (MGRX) Common Equity (2023 - 2025)
Mangoceuticals (MGRX) has disclosed Common Equity for 3 consecutive years, with $15.2 million as the latest value for Q4 2025.
- Quarterly Common Equity rose 8.99% to $15.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.2 million through Dec 2025, up 8.99% year-over-year, with the annual reading at $15.2 million for FY2025, 8.99% up from the prior year.
- Common Equity hit $15.2 million in Q4 2025 for Mangoceuticals, down from $15.7 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $20.3 million in Q1 2025 to a low of -$958468.0 in Q1 2024.
- Historically, Common Equity has averaged $10.0 million across 3 years, with a median of $13.8 million in 2024.
- Biggest five-year swings in Common Equity: tumbled 125.1% in 2024 and later soared 2212.82% in 2025.
- Year by year, Common Equity stood at $774754.0 in 2023, then skyrocketed by 1700.07% to $13.9 million in 2024, then increased by 8.99% to $15.2 million in 2025.
- Business Quant data shows Common Equity for MGRX at $15.2 million in Q4 2025, $15.7 million in Q3 2025, and $19.2 million in Q2 2025.